ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$303.96
5.26 (1.76%)
▲
5d:
-1.78%
30d:
+15.31%
90d:
-1.84%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
22d
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 6.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 6.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$473.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$294.25
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $303.96, which is considered extended relative to its 30-day fair value range of $265.69 to $296.75. From a valuation perspective, the stock is trading at a discount (Forward PE: 30.7) compared to its historical average (37.9). Remarkably, the market is currently pricing in an annual earnings decline of 6.8% over the next few years. This pessimistic expectation contrasts with the company's recent 16970.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a downtrend. Immediate support is located at $283.07, while resistance sits at $316.00.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $413.05 (+38.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ONC is in a downtrend. Immediate support is located at $283.07, while resistance sits at $316.00.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $413.05 (+38.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$265.69 -
$296.75
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.3% below Wall St target ($413.05)
Trading Range Analysis
30-Day Trading Range
$265.69 -
$296.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$283.07
Resistance Level
$316.00
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.69
Wall Street Target
$413.05
(+38.3%)
Revenue Growth (YoY)
35.5%
Earnings Growth (YoY)
16970.8%
Profit Margin
8.9%
Valuation Discount vs History
-6.8% cheaper
PE vs Historical
30.7 vs 37.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.8%
(market-implied from PE analysis)
1-Year Target
$278.39
(-7%)
2-Year Target
$259.46
(-13%)
3-Year Target
$241.81
(-19%)
3-Yr Target (if PE normalizes)
(PE: 31→38)
$298.66
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.7, Growth: 51.4%)
$1008.11
(+238%)
Base:
(SPY PE: 21.8, Growth: 51.4%)
$715.51
(+140%)
Bear:
(PE: 18.5, Growth: 51.4%)
$608.19
(+104%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (31x PE) as earnings recover.
Forward PE: 45.87 | Forward EPS (Implied): $6.51
Bull Case
$360.68
(+21%)
Analyst growth 15.0%, PE expands to 48.2
Base Case
$298.70
(0%)
Market implied 0.0%, PE stable at 45.9
Bear Case
$228.51
(-24%)
Severe decline -15.0%, PE contracts to 41.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 30.7 to 37.9
Stabilization Target:
$368.91
(+23.5%)
PE Expansion Potential:
+23.5%
Share & Embed Analysis
Last updated: July 13, 2026 4:21 PM ET
Data refreshes hourly during market hours. Next update: 5:21 PM
Data refreshes hourly during market hours. Next update: 5:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Chan Henry Lee
SELL
1660 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |